Navigation Links
PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans
Date:11/17/2010

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans. Some patients with a range of solid tumours, many of whom had been treated unsuccessfully for their cancer with other therapies, have seen their tumours shrink or stabilise for periods of between 46 days to more than a year. The research will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Thursday).

Laboratory studies of the drug, MK-4827, have shown that it inhibits proteins called PARP1 and PARP2 (poly(ADP)-ribose polymerase). PARP is involved in a number of cellular processes and one of its important functions is to assist in the repair of single-strand breaks in DNA. If one single-strand broken DNA is replicated (replication occurs before cell division) then it results in a double-strand break. By inhibiting the action of PARP, double-strand breaks occur, leading to cell death. Tumours that are caused by a mutation in the BRCA1 or BRCA2 genes are susceptible to cell death through PARP inhibition because correctly functioning BRCA genes assist in repairing double-strand DNA breaks via a process called homologous-recombination-dependent DNA repair, whereas mutated versions are unable to perform this role. Normal cells don't replicate as often as cancer cells and they still have homologous repair operating; this enables them to survive the inhibition of PARP and makes PARP a good target for anti-cancer therapy.

In a Phase I trial conducted at the H Lee Moffitt Cancer Center (Tampa Florida, USA), University of Wisconsin-Madison (Madison, USA) and the Royal Marsden Hospital (London, UK), MK-4827 was given to 59 patients (46 women, 13 men) with a range of solid tumours such as non-small cell lung cancer (NSCLC), prostate cancer, sarcoma, melanoma and breast and ovarian cancers. Some patients had cancers caused by mutations in the BRCA1/2 genes, such as breast and ovarian cancer, but others had cancers that had arisen sporadically.

The drug was given in pill form once a day, and the researchers found that the maximum tolerated dose was 300 mg a day. Dr Robert Wenham, Clinical Director for Gynecologic Oncology in the Department of Women's Oncology at the Moffitt Cancer Center, who is presenting data on behalf of the participating investigators, said: "MK-4827 is generally well tolerated, with the main dose-limiting toxicity being thrombocytopenia an abnormal decrease in the number of platelets in the circulatory blood. The most common side effects are mild nausea, vomiting, anorexia and fatigue."

The researchers saw anti-tumour responses in both sporadic and BRCA1/2 mutation-associated cancers. Ten patients with breast and ovarian cancers had partial responses, with progression-free survival between 51-445 days, and seven of these patients are still responding to treatment. Four patients (two with ovarian cancer and two with NSCLC) had stable disease for between 130-353 days.

Dr Wenham said: "Most patients in the trial had exhausted standard therapies and those who responded to this drug have benefited. Several patients have been receiving treatment for more than a year. The responses mean that MK-4827 is working as hoped and justify additional studies. Just how well MK-4827 works compared to other treatments is the goal of the next set of studies."

He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP inhibition. "BRCA is a tumour suppressor gene that assists in repairing double stranded DNA breaks. In BRCA-mutation related cancers, loss of both copies of the gene results in a non-functional protein and thus BRCA deficiency. Because BRCA works with other proteins, BRCA-pathway related deficiency can be seen in the absence of two mutated copies of the BRCA genes. This may explain why responses have been reported for this class of drugs in non-BRCA mutant cancers."

Dr Wenham and his colleagues are recruiting more patients for additional studies and an expansion of the existing trial. "We want to understand what types of cancers will respond best to treatment with MK-4827," he said. "Cohorts are currently open for patients with ovarian cancer patients without germ-line BRCA mutations, and prostate cancer patients. Cohorts will open soon for patients with T-cell prolymphocytic leukaemia, endometrial cancer, breast cancer and colorectal cancer. MK-4827 is also being studied in combination with conventional chemotherapy drugs."


'/>"/>

Contact: Emma Mason
wordmason@mac.om
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Wake up, Mom -- study shows gender differences in sleep interruptions
2. Depression linked to HIV risk among South African young people, study shows
3. Gene Therapy Shows Potential Against Heart Failure
4. New treatment for lung cancer shows promise
5. Adding pharmacists to docs offices helps patient outcomes, study shows
6. Hurdles ahead for health care reform primary care model, U-M study shows
7. Pleasurable behaviors reduce stress via brain pathways, research shows
8. New Tool for Rapid Screening of Dementia Shows Promise
9. Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage
10. Few eligible young women choose to take HPV vaccine to prevent cervical cancer, study shows
11. Research shows gene-based test can prioritize smokers for lung cancer CT screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a Telly ... over four countries and millions of viewers in a partnership with the Amazon Video ... On-Demand and fully available on Blu Ray disc in 2018. Proceeds will be going ...
(Date:8/16/2017)... ... 2017 , ... Richard Strawn’s new book Surgical Psalms ... a cancer diagnosis, surgery and recovery, the Psalms provided encouragement and hope, as ... shows love to those who are sick., Surgical Psalms contains 36 reflections about ...
(Date:8/16/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to Test Country, ... the United States has undergone major changes over the last decade, particularly when it ... order to get a blood test or other lab work done. Today, most tests ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... opportunity for men and women to train as hospice volunteers. Volunteers provide much ... illness. For over 30 years, the agency has trained volunteers to be vital ...
(Date:8/16/2017)... ... 2017 , ... First Choice Emergency Room , the largest network of ... the new Medical Director of its Sienna Plantation facility. , “We are pleased ... Plantation location,” said Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
Breaking Medicine Technology: